Clinical Trial Update: Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD [Phase 4]

View source ↗

Summary

A Phase 4 dose-optimization study of Vyvanse (lisdexamfetamine dimesylate) in children aged 6-12 with ADHD completed with posted results in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Vyvanse (lisdexamfetamine dimesylate)

Snippet

Sponsor: Shire | Conditions: Attention Deficit Hyperactivity Disorder (ADHD) | Phase 4 | Status: COMPLETED | Results posted: 2009-09-01